(AOF) – “Given cash and cash equivalents of 3 million euros as of June 30, 2023”, TME Pharma “has financial visibility until February 2024”. This is what the biotech specialist in the fight against cancer announces in the presentation of its half-year results: it records a net loss of 2.8 million euros without having achieved any turnover. “The company believes that with its lean structure and the value created through its clinical performance, it is now better positioned in terms of attractiveness to investors.”
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
This is a Smartvoice article: see legal notices